Healthcare provider profile · identity verified

Heidi Matus, MD

Internal Medicine · DENVER, CO · NPI 1063674851

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	265	74
Levothyroxine Sodium	Levothyroxine Sodium	144	40
Losartan Potassium	Losartan Potassium	127	37
Amlodipine Besylate	Amlodipine Besylate	121	36
Gabapentin	Gabapentin	105	26
Rosuvastatin Calcium	Rosuvastatin Calcium	104	32
Lisinopril	Lisinopril	94	27
Tramadol Hcl	Tramadol Hcl	78	15
Omeprazole	Omeprazole	77	23
Synthroid	Levothyroxine Sodium	74	18
Pantoprazole Sodium	Pantoprazole Sodium	68	21
Eliquis	Apixaban	66	15
Celecoxib	Celecoxib	65	15
Metoprolol Succinate	Metoprolol Succinate	56	18
Montelukast Sodium	Montelukast Sodium	53	14
Trazodone Hcl	Trazodone Hcl	52	suppressed
Metformin Hcl	Metformin Hcl	51	19
Ozempic	Semaglutide	49	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	47	15
Clopidogrel	Clopidogrel Bisulfate	45	suppressed
Mirtazapine	Mirtazapine	41	suppressed
Alprazolam	Alprazolam	40	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	40	12
Pregabalin	Pregabalin	40	suppressed
Carvedilol	Carvedilol	39	12
Furosemide	Furosemide	39	11
Clonazepam	Clonazepam	37	11
Nifedipine Er	Nifedipine	37	suppressed
Valsartan	Valsartan	37	13
Myrbetriq	Mirabegron	36	suppressed
Simvastatin	Simvastatin	34	suppressed
Ezetimibe	Ezetimibe	33	12
Potassium Chloride	Potassium Chloride	33	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	suppressed
Xarelto	Rivaroxaban	28	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Finasteride	Finasteride	26	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	18
Buspirone Hcl	Buspirone Hcl	23	suppressed
Sertraline Hcl	Sertraline Hcl	23	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	22	20
Famotidine	Famotidine	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	18	suppressed
Premarin	Estrogens, Conjugated	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Temazepam	Temazepam	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Jardiance	Empagliflozin	15	suppressed
Unithroid	Levothyroxine Sodium	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Baclofen	Baclofen	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Estradiol	Estradiol	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	11	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Atenolol	Atenolol	11	suppressed
Diazepam	Diazepam	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Methylprednisolone	Methylprednisolone	11	suppressed
Relistor	Methylnaltrexone Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error